Keeping our depressed patients in the right treatment long enough for them to get better: some hopeful findings.
Mary Anne
MA
Badaracco
D000328:Adult; D015283:Citalopram / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000235:genetics / Q000523:psychology / Q000628:therapy*; D005819:Genetic Markers; D005838:Genotype; D006266:Health Education / Q000379:methods; D006801:Humans; D010352:Patient Dropouts / Q000706:statistics & numerical data; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011613:Psychotherapy / Q000379:methods*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D018092:Kainic Acid Receptors / Q000235:genetics; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D015283:Citalopram; D005819:Genetic Markers; D018092:Kainic Acid Receptors; D017367:Selective Serotonin Reuptake Inhibitors; C514872:GRIK4 protein, human